Broadly neutralizing antibody-mediated protection against simian-HIV infection among macaques with vaginal sexually transmitted infections

Objective: Sexually transmitted infections (STIs) increase mucosal HIV infection risk and have the potential to reduce preexposure prophylaxis efficacy. Clinical trials of a broadly neutralizing antibody (bNAb) provided proof-of-concept that passive immunization against HIV can be efficacious in people. We sought to evaluate preclinically the protective efficacy of passive bNAb immunization against simian-human immunodeficiency virus (SHIV) infection in the context of concurrent vaginal STIs. Design: Using a macaque model of combined ulcerative and nonulcerative vaginal STIs caused by Treponema pallidum, Chlamydia trachomatis, and Trichomonas vaginalis, we determined the protection that passively administered bNAb 10-1074 conferred against repeated vaginal SHIV challenges and compared correlates of protection to contemporaneous and historical controls without STIs. Methods: Plasma viremia was monitored via RT-qPCR assay. Concentrations of 10-1074 were determined longitudinally in plasma samples via TZM-bl pseudovirus neutralization assay. Results: Among macaques with vaginal STIs, a single subcutaneous injection of 10-1074 durably protected against vaginal SHIV acquisition, as compared with untreated controls. Interestingly, the median plasma concentration of 10-1074 at the time of SHIV breakthrough among macaques with STIs was significantly higher (10-fold) than that previously observed among 10-1074-treated macaques in the absence of STIs. Conclusion: Passive immunization with 10-1074 conferred significant protection against repeated vaginal SHIV challenges among macaques harboring vaginal STIs. However, our findings suggest that higher bNAb concentrations may be required for prophylaxis when STIs are present. Our findings potentially impact dose selection for the clinical development of bNAbs and highlight the importance of additional preclinical efficacy testing in STI models.

[1]  W. Heneine,et al.  Sexually transmitted infections and depot medroxyprogesterone acetate do not impact protection from simian HIV acquisition by long-acting cabotegravir in macaques , 2021, AIDS.

[2]  W. Heneine,et al.  Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. , 2021, AIDS.

[3]  Allan C. deCamp,et al.  Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. , 2021, The New England journal of medicine.

[4]  E. Karita,et al.  Genital abnormalities, hormonal contraception, and HIV transmission risk in Rwandan serodifferent couples. , 2021, The Journal of infectious diseases.

[5]  W. Heneine,et al.  Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies , 2020, Nature Communications.

[6]  Taina T. Immonen,et al.  In Vivo Validation of the Viral Barcoding of Simian Immunodeficiency Virus SIVmac239 and the Development of New Barcoded SIV and Subtype B and C Simian-Human Immunodeficiency Viruses , 2019, Journal of Virology.

[7]  Myron S. Cohen,et al.  Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy , 2019, Journal of the International AIDS Society.

[8]  M. Nussenzweig,et al.  Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic , 2019, Nature Medicine.

[9]  D. Burton,et al.  Recent progress in broadly neutralizing antibodies to HIV , 2018, Nature Immunology.

[10]  J. Mcnicholl,et al.  A Nonhuman Primate Model for Rectally Transmitted Syphilis , 2018, The Journal of infectious diseases.

[11]  W. Heneine,et al.  Topical tenofovir protects against vaginal simian HIV infection in macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis , 2017, AIDS.

[12]  Ben Murrell,et al.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals , 2017, Nature Medicine.

[13]  J. Mcnicholl,et al.  A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk , 2016, Journal of acquired immune deficiency syndromes.

[14]  W. Heneine,et al.  Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis. , 2016, The Journal of infectious diseases.

[15]  J. Mascola,et al.  A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges , 2016, Nature.

[16]  J. Papp,et al.  Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis. , 2014, The Journal of infectious diseases.

[17]  Octavio A. Quiñones,et al.  Molecularly Tagged Simian Immunodeficiency Virus SIVmac239 Synthetic Swarm for Tracking Independent Infection Events , 2014, Journal of Virology.

[18]  W. Heneine,et al.  High Susceptibility to Repeated, Low-Dose, Vaginal SHIV Exposure Late in the Luteal Phase of the Menstrual Cycle of Pigtail Macaques , 2011, Journal of acquired immune deficiency syndromes.

[19]  K. Venkatesh,et al.  Interactions of HIV, Other Sexually Transmitted Diseases, and Genital Tract Inflammation Facilitating Local Pathogen Transmission and Acquisition , 2011, American journal of reproductive immunology.

[20]  Cynthia A. Derdeyn,et al.  Inflammatory Genital Infections Mitigate a Severe Genetic Bottleneck in Heterosexual Transmission of Subtype A and C HIV-1 , 2009, PLoS pathogens.

[21]  A. Haase.  Perils at mucosal front lines for HIV and SIV and their hosts , 2005, Nature Reviews Immunology.

[22]  W. Stamm,et al.  Significant reduction in inflammatory response in the macaque model of chlamydial pelvic inflammatory disease with azithromycin treatment. , 2005, The Journal of infectious diseases.

[23]  R. Veazey,et al.  Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. , 1998, AIDS research and human retroviruses.

[24]  D. Ho,et al.  Progesterone implants enhance SIV vaginal transmission and early virus load , 1996, Nature Medicine.